Guanhao Biotech Co.,Ltd. (SHE:300238)

Market Cap	3.97B +21.0%
Revenue (ttm)	387.75M +2.7%
Net Income	24.35M -11.2%
EPS	0.09 -10.0%
Shares Out	265.16M
PE Ratio	166.56
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	6,693,570
Average Volume	8,658,835
Open	14.88
Previous Close	14.99
Day's Range	14.62 - 15.08
52-Week Range	10.17 - 19.98
Beta	0.33
RSI	45.05
Earnings Date	Mar 26, 2026

About Guanhao Biotech

Guanhao Biotech Co.,Ltd. develops, manufactures, and sells regenerative medicines and life sciences products primarily in China. It offers NormalGEN, a dura repair patch; GrandNeuro, a dura repair patch; ThormalGEN, a surgical patch; DermalGEN, a wound dressing product; IREAL breast patch; and Youvision corneal graft, as well as license in intraocular lenses. The company also provides Biological dura, a spinal patch; Type B dura, a spinal patch; Sterile Bio Wound Membrane; Ario Mesh; Thoracic Surgery Repair Diaphragm; and Cympic Benvimod Cream ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1999
• Employees: 530
• Stock Exchange: Shenzhen Stock Exchange
• Ticker Symbol: 300238

Financial Performance

In 2025, Guanhao Biotech's revenue was 387.75 million, an increase of 2.72% compared to the previous year's 377.48 million. Earnings were 24.35 million, a decrease of -11.20%.